Protagonist (PTGX) | Stock Overview & Key Data
Protagonist Performance Comparison
Stock Range
Today's Range
Low: $56.10
High: $57.72
on August 22, 2025
52 Week Range
Low: $33.31
High: $60.60
on November 19, 2024
on March 12, 2025
All-Time High: $60.60 on March 10, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$3.5B
EPS
0.73
P/E Ratio (TTM)
77.00
Forward P/E
-39.31
P/B Ratio
5.23
PEG Ratio
7.70
Div. Yield
N/A
ROE
8.61%
Beta
2.333
Debt to Equity
1.69
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-758.04%
Profit Margin
24.88%
Returns and Earnings
Return on Assets (TTM)
2.25%
Return on Equity (TTM)
8.61%
EBITDA
$255.7M
Net Income (TTM)
$52.0M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$3.43
Quarterly Revenue Growth (YoY)
33.10%
Quarterly Earnings Growth (YoY)
33.09%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Protagonist PTGX | 3.50B Mid-cap | 2.51% | 4.53% | 25.20% | 59.67% | 47.46% | 37.91% | 516.08% | 157.76% |
| Vertex VRTX | 100.19B Large-cap | 0.62% | -15.94% | -8.94% | -17.95% | -2.60% | -17.90% | 40.27% | 46.36% |
| Regeneron REGN | 62.88B Large-cap | 1.56% | 5.09% | -1.23% | -17.35% | -17.58% | -50.84% | -1.12% | -2.18% |
| BridgeBio Pharma BBIO | 9.58B Mid-cap | -4.36% | 7.23% | 48.86% | 35.39% | 74.04% | 93.99% | 368.51% | 65.93% |
| Madrigal MDGL | 8.46B Mid-cap | 12.12% | 32.32% | 51.70% | 28.73% | 32.16% | 64.07% | 491.89% | 288.86% |
| Blueprint Medicines BPMC | 8.37B Mid-cap | 0.12% | 1.05% | 53.79% | 15.63% | 48.46% | 12.60% | 149.54% | 73.38% |
Ownership & Short Interest
Insider Ownership
1.03%
Institutional Ownership
116.15%
Shares Short
6M
Short Ratio
7.93
Short % of Shares Outstanding
11.10%
Average 10-Day Volume
651K
Average 90-Day Volume
648K
Protagonist Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Protagonist would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is PTGX's 52-week high and low?
- In the last 52 weeks, Protagonist reached a high of $60.60 (on March 12, 2025) and a low of $33.31 (on November 19, 2024).
- What is the market cap and P/E ratio for PTGX?
- Curious about Protagonist's size and valuation? Its market capitalization stands at 3.50B. When it comes to valuation, the P/E ratio (trailing twelve months) is 77.00, and the forward P/E (looking ahead) is -39.31.
- Does PTGX pay dividends? If so, what's the yield?
- As for dividends, Protagonist isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Protagonist's main competitors or similar companies to consider before investing?
When looking at Protagonist, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX100.19B Healthcare Biotechnology -17.90% 40.27% Regeneron
REGN62.88B Healthcare Biotechnology -50.84% -1.12% BridgeBio Pharma
BBIO9.58B Healthcare Biotechnology 93.99% 368.51% Madrigal
MDGL8.46B Healthcare Biotechnology 64.07% 491.89% Blueprint Medicines
BPMC8.37B Healthcare Biotechnology 12.60% 149.54% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Protagonist Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Protagonist's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 8.61%, the Debt to Equity ratio from the most recent quarter is 1.69, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for PTGX?
- Looking at Protagonist's growth, its revenue over the trailing twelve months (TTM) was $209M. Compared to the same quarter last year (YoY), quarterly revenue grew by 33.10%, and quarterly earnings saw a YoY growth of 33.09%.
- How much of PTGX stock is held by insiders and institutions?
- Wondering who owns Protagonist stock? Company insiders (like executives and directors) hold about 1.03% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 116.15%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.